The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
The closing price of Relay Therapeutics Inc (NASDAQ: RLAY) was $2.93 for the day, up 6.55% from the previous closing price of $2.75. In other words, the price has increased by $6.55 from its previous closing price. On the day, 1.95 million shares were traded. RLAY stock price reached its highest trading level at $2.95 during the session, while it also had its lowest trading level at $2.72.
Ratios:
Our analysis of RLAY’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 15.95 and its Current Ratio is at 15.95. In the meantime, Its Debt-to-Equity ratio is 0.06 whereas as Long-Term Debt/Eq ratio is at 0.05.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Wells Fargo on April 17, 2025, initiated with a Equal Weight rating and assigned the stock a target price of $4.
On September 10, 2024, Jefferies Upgraded its rating to Buy which previously was Hold and also upped its target price recommendation from $10.60 to $16.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Mar 27 ’25 when Bergstrom Donald A sold 986 shares for $2.84 per share. The transaction valued at 2,800 led to the insider holds 615,052 shares of the business.
Rahmer Peter sold 247 shares of RLAY for $701 on Mar 27 ’25. The insider now owns 402,184 shares after completing the transaction at $2.84 per share. On Mar 27 ’25, another insider, Catinazzo Thomas, who serves as the Chief Financial Officer of the company, sold 4,864 shares for $2.84 each. As a result, the insider received 13,814 and left with 374,567 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RLAY now has a Market Capitalization of 496699456 and an Enterprise Value of -236121984. For the stock, the TTM Price-to-Sale (P/S) ratio is 49.62 while its Price-to-Book (P/B) ratio in mrq is 0.63. Its current Enterprise Value per Revenue stands at -23.596 whereas that against EBITDA is 0.621.
Stock Price History:
The Beta on a monthly basis for RLAY is 1.54, which has changed by -0.5385827 over the last 52 weeks, in comparison to a change of 0.042615533 over the same period for the S&P500. Over the past 52 weeks, RLAY has reached a high of $10.72, while it has fallen to a 52-week low of $1.77. The 50-Day Moving Average of the stock is -7.26%, while the 200-Day Moving Average is calculated to be -45.69%.
Shares Statistics:
RLAY traded an average of 2.32M shares per day over the past three months and 2604190 shares per day over the past ten days. A total of 167.76M shares are outstanding, with a floating share count of 127.70M. Insiders hold about 24.67% of the company’s shares, while institutions hold 80.04% stake in the company. Shares short for RLAY as of 1743379200 were 18058839 with a Short Ratio of 7.79, compared to 1740700800 on 16188685. Therefore, it implies a Short% of Shares Outstanding of 18058839 and a Short% of Float of 12.889999999999999.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
